Adriamycin resistance-associated prohibitin gene inhibits proliferation of human osteosarcoma MG63 cells by interacting with oncogenes and tumor suppressor genes

Du,Min‑Dong; He,Kai‑Yi; Qin,Gang; Chen,Jin; Li,Jin‑Yi

doi:10.3892/ol.2016.4862

Adriamycin resistance-associated prohibitin gene inhibits proliferation of human osteosarcoma MG63 cells by interacting with oncogenes and tumor suppressor genes

Authors:
- Min‑Dong Du
- Kai‑Yi He
- Gang Qin
- Jin Chen
- Jin‑Yi Li
View Affiliations

Affiliations: Department of Osteoarthrosis, The First Affiliated Hospital of Guangxi Traditional Chinese Medical University, Nanning, Guangxi 530023, P.R. China
Published online on: July 14, 2016 https://doi.org/10.3892/ol.2016.4862
Pages: 1994-2000

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The resistance of cancer cells to chemotherapeutic agents is a major obstacle for successful chemotherapy, and the mechanism of chemoresistance remains unclear. The present study developed an adriamycin-resistant human osteosarcoma MG-63 sub-line (MG-63/ADR), and identified differentially expressed proteins that may be associated with adriamycin resistance. Two dimensional gel electrophoresis, matrix‑assisted laser desorption ionization time‑of‑flight mass spectrometry analysis and a protein identification assay were performed. Western blot analysis was used to examine the prohibitin (PHB) levels in the MG‑63/ADR cells. Quantitative polymerase chain reaction was utilized to detect adriamycin resistant-associated genes. Laser-scanning confocal microscope was employed to examine the colocalization of PHB with v‑myc avian myelocytomatosis viral oncogene homolog (c‑myc), FBJ murine osteosarcoma viral oncogene homolog (c‑fos), tumor protein p53 and retinoblastoma 1 (Rb). In addition, the full length of the open reading frame of human PHB was subcloned into a lentiviral vector pLVX-puro. The proliferative rate of MG‑63 cells was also investigated. The overall protein expression in MG‑63/ADR cells was clearly suppressed. Three notable protein regions, representing high mobility group box 1, Ras homolog gene family, member A, and PHB, were identified to be significantly altered in MG‑63/ADR cells when compared with its parental cells. Therefore, PHB modulated the chemoresistance of MG‑63/ADR cells by interacting with multiple oncogenes or tumor suppressor genes (c‑myc, c‑fos, p53 and Rb). In addition, overexpression of PHB decreases the proliferative rate of MG‑63 cells. In conclusion, PHB is an adriamycin resistance‑associated gene, which may inhibit the proliferation of human osteosarcoma MG-63 cells by interacting with the oncogenes or tumor suppressor genes, c‑myc, c-fos, p53 and Rb.

View Figures

View References

1	Saleh EM, El-Awady RA and Anis N: Predictive markers for the response to 5-fluorouracil therapy in cancer cells: Constant-field gel electrophoresis as a tool for prediction of response to 5-fluorouracil-based chemotherapy. Oncol Lett. 5:321–327. 2013.PubMed/NCBI
2	Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, et al: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European osteosarcoma intergroup. J Natl Cancer Inst. 99:112–128. 2007. View Article : Google Scholar : PubMed/NCBI
3	Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, et al: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 65:1748–1754. 2005. View Article : Google Scholar : PubMed/NCBI
4	Scotlandi K, Serra M, Nicoletti G, Vaccari M, Manara MC, Nini G, Landuzzi L, Colacci A, Bacci G, Bertoni F, et al: Multidrug resistance and malignancy in human osteosarcoma. Cancer Res. 56:2434–2439. 1996.PubMed/NCBI
5	Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR and Iwakuma T: CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 70:4602–4612. 2010. View Article : Google Scholar : PubMed/NCBI
6	Zhou J, Wei YH, Liao MY, Xiong Y, Li JL and Cai HB: Identification of cisplatin-resistance associated genes through proteomic analysis of human ovarian cancer cells and a cisplatin-resistant subline. Asian Pac J Cancer Prev. 13:6435–6439. 2012. View Article : Google Scholar : PubMed/NCBI
7	Zhang X, Yashiro M, Qiu H, Nishii T, Matsuzaki T and Hirakawa K: Establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res. 30:915–921. 2010.PubMed/NCBI
8	Görg A, Drews O, Lück C, Weikand F and Weiss W: 2-DE with IPGs. Electrophoresis. 30(Suppl 1): S122–S132. 2009. View Article : Google Scholar : PubMed/NCBI
9	Dannenberg JH, David G, Zhong S, van der Torre J, Wong WH and Depinho RA: mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival. Genes Dev. 19:1581–1595. 2005. View Article : Google Scholar : PubMed/NCBI
10	Chen Y, Yang Y, Yuan Z, Wang C and Shi Y: Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry. Oncol Lett. 3:1011–1016. 2012.PubMed/NCBI
11	Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE and Link MP: Pediatric Oncology Group: Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric oncology group study POG-8651. J Clin Oncol. 21:1574–1580. 2003. View Article : Google Scholar : PubMed/NCBI
12	Jaffe AB and Hall A: Rho GTPases: Biochemistry and biology. Annu Rev Cell Dev Biol. 21:247–269. 2005. View Article : Google Scholar : PubMed/NCBI
13	Wheeler AP and Ridley AJ: Why three Rho proteins? RhoA, RhoB, RhoC and cell motility. Exp Cell Res. 301:43–49. 2004. View Article : Google Scholar : PubMed/NCBI
14	Aznar S and Lacal JC: Rho signals to cell growth and apoptosis. Cancer Lett. 165:1–10. 2001. View Article : Google Scholar : PubMed/NCBI
15	Adamson P, Paterson HF and Hall A: Intracellular localization of the P21rho proteins. J Cell Biol. 119:617–627. 1992. View Article : Google Scholar : PubMed/NCBI
16	Simpson KJ, Dugan AS and Mercurio AM: Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res. 64:8694–8701. 2004. View Article : Google Scholar : PubMed/NCBI
17	Vega FM, Fruhwirth G, Ng T and Ridley AJ: RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. J Cell Biol. 193:655–665. 2011. View Article : Google Scholar : PubMed/NCBI
18	Cho HJ, Baek KE, Park SM, Kim IK, Nam IK, Choi YL, Park SH, Im MJ, Choi J, Ryu J, et al: RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett. 311:48–56. 2011. View Article : Google Scholar : PubMed/NCBI
19	Costello PS, Cleverley SC, Galandrini R, Henning SW and Cantrell DA: The GTPase rho controls a p53-dependent survival checkpoint during thymopoiesis. J Exp Med. 192:77–85. 2000. View Article : Google Scholar : PubMed/NCBI
20	Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol. 5:331–342. 2005. View Article : Google Scholar : PubMed/NCBI
21	Wang W, Jiang H, Zhu H, Zhang H, Gong J, Zhang L and Ding Q: Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett. 5:884–888. 2013.PubMed/NCBI
22	Cunha C, Carvalho A, Esposito A, Bistoni F and Romani L: DAMP signaling in fungal infections and diseases. Front Immunol. 3:2862012. View Article : Google Scholar : PubMed/NCBI
23	White E and DiPaola RS: The double-edged sword of autophagy modulation in cancer. Clin Cancer Res. 15:5308–5316. 2009. View Article : Google Scholar : PubMed/NCBI
24	Livesey KM, Tang D, Zeh HJ and Lotze MT: Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs. 10:1269–1279. 2009.PubMed/NCBI
25	Xie M, Kang R, Yu Y, Zhu S, He YL, Xu WQ, Tang DL and Cao LZ: Enhancive effect of HMGB1 gene silence on adriamycin-induced apoptosis in K562/A02 drug resistance leukemia cells. Zhonghua Xue Ye Xue Za Zhi. 29:549–552. 2008.(In Chinese). PubMed/NCBI
26	Yu Y, Xie M, He YL, Xu WQ, Zhu S and Cao LZ: Role of high mobility group box 1 in adriamycin-induced apoptosis in leukemia K562 cells. Ai Zheng. 27:929–933. 2008.(In Chinese). PubMed/NCBI
27	Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar : PubMed/NCBI
28	Huang J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D and Ni J: Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy. 8:275–277. 2012. View Article : Google Scholar : PubMed/NCBI
29	Dell'Orco RT, McClung JK, Jupe ER and Liu XT: Prohibitin and the senescent phenotype. Exp Gerontol. 31:245–252. 1996. View Article : Google Scholar : PubMed/NCBI
30	Coates PJ, Nenutil R, McGregor A, Picksley SM, Crouch DH, Hall PA and Wright EG: Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res. 265:262–273. 2001. View Article : Google Scholar : PubMed/NCBI
31	Czarnecka AM, Campanella C, Zummo G and Cappello F: Mitochondrial chaperones in cancer: From molecular biology to clinical diagnostics. Cancer Biol Ther. 5:714–720. 2006. View Article : Google Scholar : PubMed/NCBI
32	Rizwani W, Alexandrow M and Chellappan S: Prohibitin physically interacts with MCM proteins and inhibits mammalian DNA replication. Cell Cycle. 8:1621–1629. 2009. View Article : Google Scholar : PubMed/NCBI
33	Zhou TB and Qin YH: Signaling pathways of prohibitin and its role in diseases. J Recept Signal Transduct Res. 33:28–36. 2013. View Article : Google Scholar : PubMed/NCBI
34	Gogvadze V, Orrenius S and Zhivotovsky B: Mitochondria as targets for cancer chemotherapy. Semin Cancer Biol. 19:57–66. 2009. View Article : Google Scholar : PubMed/NCBI